M. Canal

Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers

P. Rosenzweig, B. Hamon-Vilcot, S. Chaufour, 1998, European Journal of Clinical Pharmacology.

A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

P. Rosenzweig, A. Patat, M. Canal, 2002, Human psychopharmacology.

Determination of betaxolol in plasma by high-performance liquid chromatography with fluorescence detection.

M. Canal, B. Flouvat, 1985, Journal of chromatography.

Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline

M. Canal, A. Dufour, B. Flouvat, 2004, European Journal of Clinical Pharmacology.

Lack of effect of amisulpride on the pharmacokinetics and safety of lithium.

C. Coulouvrat, M. Canal, E. Legangneux, 2003, The international journal of neuropsychopharmacology.

In Vivo Extrastriatal and Striatal D2 Dopamine Receptor Blockade by Amisulpride in Schizophrenia

J. Martinot, E. Artiges, M. Canal, 2001, Journal of clinical psychopharmacology.

Pharmacokinetics of Cibenzoline in Patients With Renal Impairment

M. Canal, P. Aubert, A. Baglin, 1985, Journal of clinical pharmacology.

Amisulpride does not inhibit cytochrome P450 isozymes

M. Canal, J. Thénot, G. Gillet, 2000, European Neuropsychopharmacology.